Clinical Trials Sponsored by Amicus Therapeutics
Total 7056 results
-
Amicus TherapeuticsRecruiting
-
Amicus TherapeuticsRecruitingPompe Disease (Late-onset)United States, Taiwan, Japan, Australia, Canada
-
Amicus TherapeuticsActive, not recruitingPompe Disease (Late-onset)United States, Germany, Taiwan, Belgium, Australia, Slovenia, Spain, Netherlands, Hungary, Japan, Austria, United Kingdom, France, Argentina, Canada, Sweden, Denmark, New Zealand, Greece, Korea, Republic of, Bosnia and Herzegovina, Ita... and more
-
Amicus TherapeuticsAvailablePompe Disease Infantile-OnsetTaiwan, United States, Italy
-
Amicus TherapeuticsAvailable
-
Amicus TherapeuticsActive, not recruitingBatten Disease | CLN6United States
-
Amicus TherapeuticsCompletedFabry DiseaseUnited Kingdom, United States
-
Amicus TherapeuticsApproved for marketingPhysician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry DiseaseFabry DiseaseUnited States, Australia
-
Amicus TherapeuticsCompletedFabry DiseaseAustralia, Brazil
-
Amicus TherapeuticsCompletedFabry DiseaseUnited States
-
Amicus TherapeuticsTerminatedFabry DiseaseUnited Kingdom, United States, Australia, Brazil, France
-
Amicus TherapeuticsCompletedFabry DiseaseFrance, United Kingdom
-
Amicus TherapeuticsTerminated
-
Amicus TherapeuticsCompleted
-
Amicus TherapeuticsRecruitingPompe DiseaseUnited States
-
Amicus TherapeuticsRecruitingFabry DiseaseSpain, United States, Japan, Australia, France, Portugal
-
Amicus TherapeuticsActive, not recruiting
-
Amicus TherapeuticsCompletedFabry DiseaseCanada, Belgium, United States, Australia, Netherlands
-
Amicus TherapeuticsCompletedGaucher Disease | Gaucher Disease, Type 1 | Type 1 Gaucher DiseaseUnited Kingdom, United States
-
Amicus TherapeuticsCompletedEpidermolysis BullosaUnited States
-
Amicus TherapeuticsCompleted
-
Amicus TherapeuticsCompleted
-
Amicus TherapeuticsTerminatedType 1 Gaucher DiseaseUnited States, United Kingdom
-
Amicus TherapeuticsRecruitingGlycogen Storage Disease Type II Infantile OnsetUnited States, Taiwan, France, Germany, Italy, United Kingdom
-
Amicus TherapeuticsActive, not recruitingPompe DiseaseUnited States, Netherlands, United Kingdom, Australia, Germany, New Zealand
-
Amicus TherapeuticsActive, not recruitingFabry DiseaseUnited States, United Kingdom
-
Amicus TherapeuticsCompletedPompe Disease (Late-onset)United States, Australia, Korea, Republic of, Japan, Taiwan, Belgium, Slovenia, New Zealand, United Kingdom, France, Argentina, Canada, Spain, Bosnia and Herzegovina, Germany, Sweden, Hungary, Austria, Bulgaria, Denmark, Greece, I... and more
-
Amicus TherapeuticsCompletedFabry DiseaseJapan, Taiwan, Turkey, United States, Brazil
-
Amicus TherapeuticsTerminatedBatten Disease | Neuronal Ceroid Lipofuscinosis CLN6 | Neuronal Ceroid Lipofuscinosis CLN3United States
-
Amicus TherapeuticsCompletedVariant Late-Infantile Neuronal Ceroid LipofuscinosisUnited States
-
Amicus TherapeuticsCompletedOpen-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry DiseaseFabry DiseaseUnited States, Austria, United Kingdom, Argentina, Australia, Belgium, Brazil, Canada, Denmark, Egypt, France, Italy, Japan, Spain, Turkey
-
Amicus TherapeuticsTerminatedLate-onset Pompe DiseaseUnited States, Canada, Australia, Belgium
-
Amicus TherapeuticsCompletedFabry DiseaseFrance, Austria, United States, Belgium, Japan, United Kingdom, Denmark, Brazil, Australia, Italy
-
Amicus TherapeuticsCompletedFabry DiseaseUnited States, Italy, Spain, Turkey, Brazil, Canada, United Kingdom, France, Poland, Australia, Egypt, Argentina, Denmark
-
Amicus TherapeuticsCompletedFabry DiseaseUnited States, Australia, France, United Kingdom, Brazil, Canada
-
Amicus TherapeuticsTerminatedFabry DiseaseAustralia, United States, Italy, Spain, Belgium, Turkey, Brazil, Argentina, United Kingdom, Denmark, France, Canada, Egypt
-
Amicus TherapeuticsCompleted
-
Amicus TherapeuticsCompletedGaucher Disease | Gaucher Disease, Type 1 | Type 1 Gaucher DiseaseUnited States
-
Amicus TherapeuticsCompletedGaucher Disease | Gaucher Disease, Type 1 | Type 1 Gaucher DiseaseUnited Kingdom, Israel, South Africa, United States
-
Amicus TherapeuticsCompleted
-
Amicus TherapeuticsCompleted
-
Amicus TherapeuticsCompletedGlycogen Storage Disease Type II | Pompe DiseaseUnited States
-
Amicus Therapeutics France SASActive, not recruitingFabry Disease | Anderson Fabry DiseaseFrance
-
Scioderm, Inc.Amicus TherapeuticsCompletedEpidermolysis BullosaItaly, Spain, Serbia, United States, Australia, Netherlands, Austria, Germany, Israel, Lithuania, France, United Kingdom, Poland
-
Scioderm, Inc.Amicus TherapeuticsTerminatedEpidermolysis BullosaPoland, Spain, Serbia, Netherlands, United States, Austria, Australia, Israel, Germany, France, United Kingdom, Lithuania
-
Amicus Therapeutics France SASActive, not recruiting
-
Scioderm, Inc.Amicus TherapeuticsCompletedEpidermolysis BullosaUnited States
-
Amicus TherapeuticsEngage Health Inc.CompletedFabry DiseaseUnited States
-
University Hospital MuensterAmicus TherapeuticsCompleted